See more : Morningstar Japan K.K. (4765.T) Income Statement Analysis – Financial Results
Complete financial analysis of Surgalign Holdings, Inc. (SRGA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Surgalign Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Domo, Inc. (DOMO) Income Statement Analysis – Financial Results
- Noble Helium Limited (NHE.AX) Income Statement Analysis – Financial Results
- Cass Information Systems, Inc. (CASS) Income Statement Analysis – Financial Results
- Charter Hall Social Infrastructure REIT (CQE.AX) Income Statement Analysis – Financial Results
- Halows Co.,Ltd. (2742.T) Income Statement Analysis – Financial Results
Surgalign Holdings, Inc. (SRGA)
About Surgalign Holdings, Inc.
Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops Augmented Reality and Artificial Intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.98M | 90.50M | 101.75M | 117.42M | 280.86M | 279.56M | 272.87M | 282.29M | 262.81M | 197.98M | 178.11M | 169.32M | 166.17M | 164.53M | 146.64M | 94.21M | 73.97M | 75.20M | 92.70M | 75.51M | 118.49M | 140.73M | 122.50M | 33.03M |
| Cost of Revenue | 41.69M | 29.78M | 44.00M | 32.78M | 140.73M | 137.04M | 140.52M | 132.55M | 129.01M | 117.87M | 92.90M | 92.10M | 90.17M | 87.03M | 77.82M | 56.56M | 54.65M | 55.46M | 55.53M | 42.77M | 94.31M | 112.63M | 91.28M | 18.60M |
| Gross Profit | 40.29M | 60.73M | 57.75M | 84.65M | 140.12M | 142.52M | 132.35M | 149.74M | 133.80M | 80.11M | 85.22M | 77.21M | 76.00M | 77.49M | 68.81M | 37.65M | 19.32M | 19.74M | 37.18M | 32.74M | 24.18M | 28.10M | 31.22M | 14.43M |
| Gross Profit Ratio | 49.14% | 67.10% | 56.75% | 72.09% | 49.89% | 50.98% | 48.50% | 53.04% | 50.91% | 40.46% | 47.84% | 45.60% | 45.74% | 47.10% | 46.93% | 39.97% | 26.12% | 26.25% | 40.10% | 43.36% | 20.41% | 19.96% | 25.49% | 43.69% |
| Research & Development | 15.74M | 13.89M | 11.95M | 16.84M | 14.41M | 13.38M | 16.09M | 15.07M | 15.54M | 15.24M | 12.23M | 9.81M | 9.44M | 8.90M | 8.14M | 5.19M | 5.40M | 5.00M | 3.84M | 2.44M | 2.46M | 2.63M | 2.39M | 1.68M |
| General & Administrative | 95.89M | 104.67M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.80M | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 119.22M | 115.10M | 116.13M | 107.44M | 107.65M | 81.64M | 58.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 95.89M | 104.67M | 124.39M | 135.40M | 119.22M | 115.10M | 116.13M | 107.44M | 112.45M | 81.64M | 58.40M | 55.64M | 59.23M | 59.33M | 54.17M | 31.04M | 27.25M | 23.35M | 23.22M | 23.52M | 29.24M | 35.96M | 20.58M | 9.74M |
| Other Expenses | -898.00K | -3.93M | 75.43M | 41.21M | 0.00 | 0.00 | 3.83M | 0.00 | -4.80M | 0.00 | -20.00K | 0.00 | 0.00 | 0.00 | 104.41M | 4.19M | 4.20M | 336.00K | 136.00K | 169.00K | 5.10M | 0.00 | 1.45M | 576.09K |
| Operating Expenses | 110.73M | 114.62M | 136.34M | 152.23M | 133.63M | 128.48M | 136.05M | 122.50M | 123.19M | 96.88M | 70.61M | 65.44M | 68.67M | 68.22M | 166.72M | 40.42M | 36.86M | 28.69M | 27.20M | 26.13M | 36.79M | 38.59M | 24.42M | 11.99M |
| Cost & Expenses | 152.42M | 144.40M | 180.34M | 185.01M | 274.36M | 265.52M | 276.56M | 255.06M | 252.20M | 214.75M | 163.50M | 157.55M | 158.84M | 155.26M | 244.54M | 96.97M | 91.50M | 84.15M | 82.72M | 68.89M | 131.10M | 151.22M | 115.70M | 30.59M |
| Interest Income | 0.00 | 0.00 | 92.00K | 161.00K | 35.00K | 8.00K | 8.00K | 3.00K | 9.00K | 23.00K | 185.00K | 193.00K | 114.00K | 273.00K | 567.00K | 849.00K | 934.00K | 361.00K | 96.00K | 235.00K | 186.00K | 1.31M | 1.21M | 0.00 |
| Interest Expense | 1.01M | 0.00 | 31.00K | 12.57M | 2.77M | 3.18M | 1.66M | 1.49M | 1.36M | 542.00K | 0.00 | 201.00K | 537.00K | 544.00K | 797.00K | 753.00K | 898.00K | 862.00K | 967.00K | 981.00K | 2.76M | 106.00K | 434.00K | 0.00 |
| Depreciation & Amortization | 2.16M | 2.48M | 6.67M | 22.68M | 14.57M | 14.23M | 16.51M | 16.52M | 15.40M | 12.20M | 7.99M | 8.03M | 7.50M | 7.14M | 6.16M | 5.42M | 5.33M | 4.33M | 4.06M | 4.41M | 2.89M | 2.34M | 1.45M | 576.09K |
| EBITDA | -68.28M | -3.93M | -71.92M | -181.86M | 11.76M | 43.13M | 705.00K | 41.23M | 20.94M | -16.18M | 20.44M | 19.83M | -119.76M | 16.14M | -91.63M | 3.70M | -11.27M | -4.26M | 14.13M | 11.27M | -10.89M | -124.24M | 9.46M | 2.92M |
| EBITDA Ratio | -83.29% | 20.64% | -70.68% | 111.15% | 4.19% | 15.43% | 0.26% | 14.60% | 7.97% | -8.17% | 11.47% | 11.71% | -72.07% | 9.81% | -62.49% | 3.93% | -15.23% | -5.66% | 15.24% | 14.92% | -9.19% | -4.86% | 7.72% | 8.83% |
| Operating Income | -70.44M | 16.20M | -78.59M | 107.85M | -2.50M | 28.81M | -15.68M | 24.63M | 5.63M | -28.66M | 12.24M | 11.77M | -127.38M | 9.02M | -98.36M | -2.57M | -17.53M | -8.95M | 9.98M | 6.62M | -13.97M | -10.50M | 6.80M | 2.44M |
| Operating Income Ratio | -85.92% | 17.90% | -77.24% | 91.84% | -0.89% | 10.31% | -5.75% | 8.72% | 2.14% | -14.47% | 6.87% | 6.95% | -76.65% | 5.48% | -67.08% | -2.73% | -23.70% | -11.90% | 10.76% | 8.77% | -11.79% | -7.46% | 5.55% | 7.38% |
| Total Other Income/Expenses | 14.79M | -119.86M | -119.09M | -61.00M | -1.27M | -3.09M | -1.78M | -1.41M | -1.44M | -268.00K | 204.00K | -167.00K | -419.00K | -564.00K | -230.00K | 96.00K | 36.00K | -501.00K | -871.00K | -746.00K | -2.57M | 1.21M | 774.00K | -98.15K |
| Income Before Tax | -55.65M | -123.79M | -197.68M | -242.86M | -5.58M | 25.73M | -17.46M | 23.21M | 4.19M | -28.92M | 12.44M | 11.60M | -127.79M | 8.46M | -98.59M | -2.47M | -17.50M | -9.45M | 9.11M | 5.87M | -16.54M | -9.29M | 7.58M | 2.34M |
| Income Before Tax Ratio | -67.88% | -136.79% | -194.28% | -206.82% | -1.99% | 9.20% | -6.40% | 8.22% | 1.59% | -14.61% | 6.99% | 6.85% | -76.91% | 5.14% | -67.23% | -2.62% | -23.66% | -12.56% | 9.82% | 7.78% | -13.96% | -6.60% | 6.18% | 7.09% |
| Income Tax Expense | -1.04M | -886.00K | -3.49M | 5.92M | -4.33M | 19.45M | -3.06M | 8.30M | 1.49M | -11.11M | 4.04M | 3.23M | 1.61M | 2.60M | 1.39M | -376.00K | -6.37M | -3.90M | 2.95M | -483.00K | -3.03M | -3.79M | 3.12M | -618.86K |
| Net Income | -54.61M | -122.91M | -194.20M | -248.78M | -1.25M | 6.27M | -14.40M | 14.92M | 2.70M | -17.81M | 8.40M | 8.38M | -129.40M | 5.86M | -99.98M | -2.10M | -11.13M | -5.55M | 6.16M | 6.36M | -13.51M | -5.51M | 4.46M | 2.96M |
| Net Income Ratio | -66.61% | -135.81% | -190.86% | -211.86% | -0.45% | 2.24% | -5.28% | 5.28% | 1.03% | -9.00% | 4.72% | 4.95% | -77.87% | 3.56% | -68.18% | -2.22% | -15.04% | -7.38% | 6.64% | 8.42% | -11.40% | -3.91% | 3.64% | 8.96% |
| EPS | -8.33 | -30.08 | -78.30 | -106.39 | -0.02 | 0.11 | -0.25 | 0.26 | 0.05 | -0.32 | 0.15 | 0.15 | -2.36 | 0.11 | -2.00 | -0.07 | -0.37 | -0.20 | 0.23 | 0.24 | -0.60 | -0.25 | 0.42 | 0.81 |
| EPS Diluted | -8.33 | -30.08 | -78.30 | -106.39 | -0.02 | 0.10 | -0.25 | 0.25 | 0.05 | -0.32 | 0.15 | 0.15 | -2.36 | 0.11 | -2.00 | -0.07 | -0.37 | -0.20 | 0.23 | 0.24 | -0.60 | -0.25 | 0.22 | 0.18 |
| Weighted Avg Shares Out | 6.56M | 4.09M | 2.48M | 2.34M | 63.52M | 59.68M | 58.24M | 57.61M | 56.74M | 56.26M | 55.86M | 55.15M | 54.73M | 54.35M | 49.91M | 29.82M | 29.75M | 27.75M | 26.59M | 26.37M | 22.43M | 21.76M | 10.64M | 3.67M |
| Weighted Avg Shares Out (Dil) | 6.56M | 4.09M | 2.48M | 2.34M | 63.52M | 60.60M | 58.24M | 58.59M | 56.74M | 56.26M | 56.07M | 55.35M | 54.73M | 54.77M | 49.91M | 29.82M | 29.75M | 27.75M | 27.06M | 27.00M | 22.43M | 21.76M | 20.34M | 16.64M |
Surgalign Holdings, Inc. Announces Record Date and Annual Meeting Date
Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More
7 Stocks With Insider Buying
SRGA Stock Price Increases Over 19% Pre-Market: Why It Happened
Surgalign Holdings, Inc. Announces Pricing of Public Offering of 25,000,000 Shares of its Common Stock
Surgalign Holdings Announce the Commercial Launch of ViBone® Moldable and the First Clinical Implantation
Surgalign Holdings, Inc. to Participate at the 23rd Annual ICR/Westwicke Conference
Surgalign Holdings : Strong Upside Potential
Surgalign Holdings, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Surgalign Holdings, Inc. Appoints Paul Lewicki, PhD to Board of Directors
Source: https://incomestatements.info
Category: Stock Reports